Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?
Open Access
- 30 November 2016
- journal article
- Published by Elsevier BV in The Lancet Haematology
- Vol. 4 (1), e4-e5
- https://doi.org/10.1016/s2352-3026(16)30163-6
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Treatment recommendations from the Eighth International Workshop on Waldenström’s MacroglobulinemiaBlood, 2016
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- How to manage Waldenstrom’s macroglobulinemiaLeukemia, 2013
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyBlood, 2012
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international studyBlood, 2011
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals of Oncology, 2005
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood, 2004
- Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's MacroglobulinemiaClinical Lymphoma, 2002